In contrast, SOX2-expression maintenance commits most CDX2-induced cancers to the CIN pathway, which is characterized by more frequent mutations in the tumor suppressor TP53 gene and increased frequency of copy number alterations. This evidence concerns the gene CDX2 and cancer.